Caplin Point is a fast growing, fully integrated Pharmaceutical company with a dominant presence in Latin America, Francophone Africa and a growing presence in the Regulated markets such as USA and EU. The facility has been inspected by US FDA three times since 2016 and received EIR each time. As on date, the company has filed 41 ANDAs, with 28 approvals. The facility is also approved by EU-GMP, ANVISA-Brazil, INVIMA-Colombia, COFEPRIS-Mexico, etc. Caplin Point maintains deep focus on innovative technologies and products, with a sizeable part of its annual earnings invested into Research & Development of safe and effective products across varied dosage forms.

Caplin Point是一家快速發(fā)展的綜合性制藥公司，在拉丁美洲和非洲法語(yǔ)國(guó)家占據(jù)顯著地位，并且在美國(guó)和歐盟等規(guī)范市場(chǎng)的影響力也與日俱增。自 2016 年以來(lái)，該公司的生產(chǎn)設(shè)施已接受美國(guó)FDA三次檢查，均獲得了EIR。截至目前，該公司已提交 41 份ANDA申請(qǐng)，其中 28 份已獲批。該生產(chǎn)設(shè)施還獲得了歐盟的EU-GMP、巴西ANVISA、哥倫比亞的INVIMA和墨西哥的COFEPRIS等機(jī)構(gòu)的批準(zhǔn)。Caplin Point專注于技術(shù)與產(chǎn)品的創(chuàng)新，每年將相當(dāng)一部分收益投入到各種劑型的安全有效產(chǎn)品的研發(fā)中。